Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seagen Inc
(NQ:
SGEN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Seagen Inc
< Previous
1
2
3
4
5
Next >
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
December 12, 2022
From
Seagen Inc.
Via
Business Wire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
December 01, 2022
From
Seagen Inc.
Via
Business Wire
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
November 15, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
November 10, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
November 10, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
November 10, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Names David R. Epstein as Chief Executive Officer and Director
November 10, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Reports Third Quarter 2022 Financial Results
October 27, 2022
From
Seagen Inc.
Via
Business Wire
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...
Via
FinancialNewsMedia
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022
October 06, 2022
From
Seagen Inc.
Via
Business Wire
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
September 27, 2022
From
Seagen Inc.
Via
Business Wire
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223
September 26, 2022
LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development
Via
Spotlight Growth
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
September 26, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer
September 19, 2022
From
Seagen Inc.
Via
Business Wire
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
September 12, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress
September 07, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 07, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Statement on Outcome of Daiichi Sankyo Arbitration
August 12, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Reports Second Quarter 2022 Financial Results
July 28, 2022
From
Seagen Inc.
Via
Business Wire
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
July 26, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
July 08, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
July 02, 2022
From
Seagen Inc.
Via
Business Wire
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
June 06, 2022
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
June 06, 2022
From
Genmab A/S
Via
Business Wire
ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
June 03, 2022
From
Seagen Inc.
Via
Business Wire
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
May 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
May 23, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
May 16, 2022
From
Seagen Inc.
Via
Business Wire
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
May 09, 2022
From
Seagen Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.